Markets · Asia · KSE

068270.KS Celltrion

₩179,600 -2.13%

Asia · Health Care

Log

Solid = close · dashed = 50-day MA · bars = volume. Toggle Bollinger / RSI / MACD. Hover to inspect. EOD data.

-2.13%

YTD

+8.60%

P/E

—

P/B

—

ROE

—

Div yield

—

Beta

0.47

Market cap

—

RSI (14)

Next earnings

—

Previous session

close of Oct 8, 2026 · EOD, no live order book

Open

₩182,000

₩179,600

VWAP (n/a)

—

Day high

₩182,300

Day low

₩179,500

Volume

462K

VWAP = daily turnover ÷ volume — the volume-weighted average, the closest EOD read on where trading actually clustered. A true order book is live-only and needs a broker feed. Turnover/VWAP available for MOEX listings.

Latest headlines

OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®, now commercially available in the U.S.

Yahoo Finance · Oct 5

Celltrion Expands Omlyclo® Portfolio in Europe with Launch of 300 mg Strength

Yahoo Finance · Aug 24

Celltrion to present seven abstracts in inflammatory bowel disease (IBD) at 2026 Digestive Disease Week® (DDW)

Yahoo Finance · Apr 21

Celltrion announces U.S. availability of AVTOZMA® (tocilizumab-anoh) subcutaneous (SC) formulation

Yahoo Finance · Mar 16

Celltrion presents innovative drug pipeline and U.S. manufacturing and R&D expansion strategy at the 44th Annual J.P. Morgan Healthcare Conference

Yahoo Finance · Jan 14

Celltrion to present at the 44th Annual J.P. Morgan Healthcare Conference

Yahoo Finance · Jan 6

Headlines via Yahoo Finance · links open the source · not an endorsement.

Research & reports

TradingView ↗

Charts & analysis

Yahoo Finance ↗

Quote & news

External resources — availability and opinions are theirs, not ours.

This is reference data for your own analysis — not a recommendation to buy or sell 068270.KS. Try it in the Lab to size a position and see the risk.